RTI Hoping FDA Review Can Lead To Regeneration In 2002
This article was originally published in The Gray Sheet
Executive Summary
Regeneration Technologies, Inc. says it will reclassify "certain expenses" from prior financial reports but will not have to restate any previously reported results
You may also be interested in...
CryoLife Reviewing Tissue Sterilization Process In Wake Of Warning Letter
FDA is increasing its scrutiny over validation of tissue processing practices, as evidenced by a June 17 warning letter to CryoLife
CryoLife Reviewing Tissue Sterilization Process In Wake Of Warning Letter
FDA is increasing its scrutiny over validation of tissue processing practices, as evidenced by a June 17 warning letter to CryoLife
Arrow LionHeart LVAD Trial Progress Supports 13% Stock Gain In February
Continued clinical progress in the development of Arrow's LionHeart left ventricular assist device (LVAD) as a destination therapy helped sustain a 13.2% advance in the firm's stock price in February to $45.73